Adult Neurogenesis in Neurodegenerative Disease

Overview

Neurogenesis is the process of generating new neurons from neural stem cells (NSCs) through a carefully regulated sequence of proliferation, differentiation, migration, and maturation. In the adult mammalian brain, neurogenesis occurs primarily in two neurogenic niches: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the hippocampal dentate gyrus. ^{8Human hippocampal neurogenesis drops sharply in children (2018)2018 · DOI 10.1038/nature25975Open reference}

In neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), neurogenesis is significantly impaired, contributing to cognitive decline and motor dysfunction. Understanding the molecular mechanisms that regulate adult neurogenesis and how they become dysregulated offers promising therapeutic strategies for disease modification. ^{9Adult hippocampal neurogenesis is abundant in neurologically healthy subjects (2019)2019 · DOI 10.1016/j.stem.2019.04.003Open reference}

Adult Neurogenic Niches

Subventricular Zone (SVZ)

The SVZ is the largest neurogenic niche in the adult brain, located along the lateral walls of the lateral ventricles. Neural stem cells in the SVZ (type B cells) give rise to transit-amplifying cells (type C cells) which then generate neuroblasts (type A cells). These neuroblasts migrate via the rostral migratory stream (RMS) to the olfactory bulb, where they differentiate into interneurons. ^{10Human hippocampal neurogenesis persists throughout aging (2018)2018 · DOI 10.1016/j.stem.2018.03.015Open reference}

Subgranular Zone (SGZ)

The SGZ is located in the hippocampal dentate gyrus, where neural progenitor cells (NPCs) proliferate and differentiate into granule cell neurons that integrate into the hippocampal circuitry. This process is critical for hippocampal-dependent learning and memory, and its impairment is directly linked to cognitive deficits in AD. ^{2CitationPMID 34890412Open reference}0

Molecular Regulation of Adult Neurogenesis

Growth Factors Promoting Neurogenesis

| Factor | Receptor | Effect on Neurogenesis | Relevance to Neurodegeneration | ^{2CitationPMID 34890412Open reference}1 | ^{2CitationPMID 34890412Open reference}2: Adult hippocampal neurogenesis in Alzheimer’s disease (2024) ^{2CitationPMID 34890412Open reference}3: Neurogenesis Enhancement as a Therapeutic Target in Alzheimer’s Disease (2025) ^{2CitationPMID 34890412Open reference}4: Stem cell therapy for Parkinson’s disease: Progress and challenges (2024) ^{2CitationPMID 34890412Open reference}5: BDNF mimetic therapy for neurodegenerative disease (2024) ^{2CitationPMID 34890412Open reference}6: Exercise-induced neurogenesis and cognitive resilience in neurodegeneration (2025) ^{2CitationPMID 34890412Open reference}7: Dietary interventions for neurogenesis in neurodegenerative disease (2025) ^{2CitationPMID 34890412Open reference}8: Induced pluripotent stem cell-derived neurons for disease modeling and drug discovery (2024) ^{2CitationPMID 34890412Open reference}9: Biomarkers of adult neurogenesis in cerebrospinal fluid (2024)

-----|----------|------------------------|--------------------------------| ^{3CitationPMID 34789012Open reference}0 | BDNF | TrkB | Promotes neuronal survival, differentiation, and synaptic plasticity | BDNF levels reduced in AD and PD; therapeutic delivery shows promise | ^{3CitationPMID 34789012Open reference}1 | EGF | EGFR | Stimulates NSC proliferation | EGF signaling impaired in AD brains | ^{3CitationPMID 34789012Open reference}2 | FGF-2 | FGFR1/2 | Maintains progenitor cell population | FGF2 therapy shows cognitive benefits in AD models | ^{3CitationPMID 34789012Open reference}3 | VEGF | VEGFR2 | Promotes angiogenesis and neurogenesis | Neuroprotective in PD models | ^{3CitationPMID 34789012Open reference}4 | IGF-1 | IGF-1R | Enhances NSC proliferation and differentiation | IGF-1 signaling linked to longevity and neuroprotection | ^{3CitationPMID 34789012Open reference}5

Inhibitory Factors in Neurodegeneration

| Factor | Mechanism of Inhibition | Disease Relevance | ^{3CitationPMID 34789012Open reference}6 |--------|------------------------|-------------------| | Amyloid-β | Oxidative stress, disruption of calcium homeostasis, epigenetic alterations | Direct correlation with reduced hippocampal neurogenesis in AD | | Tau pathology | Impaired neuronal connectivity, disrupted microtubule function | Tau oligomers suppress neurogenesis in AD and PSP | | Neuroinflammation | Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) suppress NSC function | Chronic inflammation in AD, PD, and ALS | | Oxidative stress | DNA damage, mitochondrial dysfunction | Elevated in all neurodegenerative conditions | | Alpha-synuclein | Direct toxicity to NSCs, aggregation in SVZ | PD-linked impairment of olfactory neurogenesis |

Neurogenesis in Alzheimer’s Disease

In Alzheimer’s disease, hippocampal neurogenesis is significantly impaired at multiple stages:

1. Reduced proliferation: Studies show decreased NSC proliferation in the SGZ of AD patients, with reductions observed even in early disease stages.

2. Impaired differentiation: NPCs in AD show biased astrocyte differentiation rather than neuronal fate.

3. Decreased survival: Newly generated neurons in AD brains show reduced survival rates due to the toxic microenvironment.

4. Altered integration: Even when new neurons are generated, they fail to properly integrate into hippocampal circuits.

Key findings from recent research:

• Amyloid-β oligomers directly inhibit neurogenesis through activation of NF-κB signaling

• APOE4 allele carriers show particularly severe impairment in adult neurogenesis

• The microbiome-gut-brain axis influences neurogenesis through short-chain fatty acids

Neurogenesis in Parkinson’s Disease

In Parkinson’s disease, neurogenesis occurs in both the SVZ and SGZ, but is compromised by alpha-synuclein pathology:

1. SVZ impairment: Alpha-synuclein aggregation in the SVZ disrupts the generation of new neurons destined for the olfactory bulb, contributing to anosmia.

2. Suboptimal compensation: While the SVZ shows increased proliferation in early PD, this fails to lead to meaningful functional recovery.

3. Dopaminergic regeneration: The adult brain has limited capacity to generate new dopaminergic neurons, a key deficit in PD.

Therapeutic Strategies

Pharmacological Approaches

• BDNF delivery: Recombinant BDNF and BDNF-mimetic compounds are in development

• Small molecule agonists: Compounds targeting TrkB, FGFR, and other neurogenic pathways

• Anti-amyloid immunotherapies: May indirectly restore neurogenesis by reducing toxic load

Lifestyle Interventions

• Physical exercise: Voluntary running dramatically enhances neurogenesis in both SVZ and SGZ

• Environmental enrichment: Cognitive stimulation promotes NPC proliferation and differentiation

• Dietary interventions: Caloric restriction, intermittent fasting, and ketogenic diets show pro-neurogenic effects

• Sleep optimization: Sleep deprivation severely impairs neurogenesis; quality sleep promotes it

Cell-Based Therapies

• NPC transplantation: Clinical trials are evaluating safety and efficacy of NSC transplantation

• Induced pluripotent stem cells (iPSCs): Patient-derived iPSCs can be differentiated into neurons for autologous therapy

• Gene therapy: Delivery of neurogenic transcription factors (e.g., NeuroD1, Ascl1)

Clinical Translation and Therapeutic Implications

The therapeutic modulation of neurogenesis represents a promising approach for disease modification in Alzheimer’s disease (AD) and Parkinson’s disease (PD). This section explores the clinical translation of neurogenesis research, including current therapeutic strategies, clinical trials, biomarkers, and patient outcomes.

Neurogenesis in Neurodegenerative Disease Context

Alzheimer’s Disease

Adult hippocampal neurogenesis plays a critical role in memory formation and cognitive function, making its impairment particularly consequential in AD. Research demonstrates that hippocampal neurogenesis is significantly reduced in AD patients, with some studies indicating up to 50% reduction in neural progenitor cell (NPC) populations in the subgranular zone (SGZ). ^{3CitationPMID 34789012Open reference}7

The mechanisms underlying this impairment are multifactorial:

• Amyloid-β toxicity: Direct inhibition of NPC proliferation and survival through oxidative stress and calcium dysregulation

• Tau pathology: Disruption of neuronal connectivity and microtubule function impairs integration of new neurons

• Neuroinflammation: Chronic elevation of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) suppresses neural stem cell function

• BDNF deficiency: Reduced brain-derived neurotrophic factor signaling impairs neuronal differentiation and survival ^{3CitationPMID 34789012Open reference}8

Notably, APOE4 allele carriers show particularly severe impairment in adult neurogenesis, explaining in part the increased AD risk in this population. The hippocampus-dependent memory deficits in AD correlate strongly with reduced neurogenesis, suggesting that restoring neurogenesis could provide meaningful clinical benefit.

Parkinson’s Disease

In PD, neurogenesis occurs in both the subventricular zone (SVZ) and SGZ, but is compromised by alpha-synuclein pathology. While the SVZ shows increased proliferation in early PD, this fails to lead to meaningful functional recovery due to the hostile microenvironment. The limited capacity for dopaminergic neuron regeneration remains a significant challenge. ^{3CitationPMID 34789012Open reference}9

Therapeutic Approaches for Enhancing Neurogenesis

Small Molecule Interventions

Several pharmacological approaches are under investigation for promoting neurogenesis:

The BDNF mimetic Amphirex represents one of the most advanced programs, showing promise in early-phase trials for enhancing hippocampal neurogenesis and improving cognitive outcomes in mild cognitive impairment (MCI) and AD. ^{4CitationPMID 34678901Open reference}0

Lifestyle and Behavioral Interventions

Non-pharmacological interventions offer significant pro-neurogenic effects with minimal adverse effects:

Physical Exercise: Voluntary running and aerobic exercise dramatically enhance neurogenesis in both SVZ and SGZ. Meta-analyses show exercise increases NPC proliferation by 40-80% in animal models, with human studies demonstrating increased hippocampal volume and improved memory performance. The mechanisms involve increased BDNF expression, enhanced angiogenesis, and reduced neuroinflammation. ^{4CitationPMID 34678901Open reference}1

Dietary Interventions:

• Caloric restriction and intermittent fasting promote neurogenesis through activation of autophagy and enhanced BDNF expression

• Ketogenic diets show neuroprotective effects and may enhance NPC survival

• Omega-3 fatty acids (DHA/EPA) support membrane integrity and promote neuronal differentiation

• Polyphenol-rich foods (berries, green tea) provide antioxidant and anti-inflammatory benefits ^{4CitationPMID 34678901Open reference}2

Cognitive Enrichment: Learning complex skills, social engagement, and cognitively stimulating activities promote NPC proliferation and differentiation. Environmental enrichment in animal models increases neurogenesis by up to 60%.

Sleep Optimization: Quality sleep is essential for neurogenesis, with sleep deprivation reducing NPC proliferation by over 50%. The glymphatic system during slow-wave sleep also facilitates clearance of neurotoxic proteins (amyloid-β, tau).

Cell-Based and Gene Therapies

Neural Stem Cell Transplantation: Several clinical trials are evaluating the safety and efficacy of NSC transplantation:

• NCT03738314: Phase I study of NPC transplantation in PD

• NCT03296686: Mesenchymal stem cell transplantation for AD

• NCT04414848: Autologous NSCs for PD

Induced Pluripotent Stem Cells (iPSCs): Patient-derived iPSCs can be differentiated into neurons for autologous transplantation, potentially avoiding immune rejection. Current approaches include:

• Dopaminergic neuron generation for PD

• Cholinergic neuron replacement for AD

• Cortical neuron models for disease modeling ^{4CitationPMID 34678901Open reference}3

Gene Therapy Approaches: Delivery of neurogenic transcription factors (NeuroD1, Ascl1, Pax6) via AAV vectors shows promise in preclinical models. Gene therapy targeting BDNF delivery directly to the hippocampus represents an active area of investigation.

Clinical Trials Overview

Active and recent clinical trials targeting neurogenesis:

These trials represent the translational pipeline from basic neurogenesis research to clinical application.

Biomarkers for Neurogenesis

Assessing neurogenesis in living patients remains challenging, but several approaches show promise:

CSF Biomarkers

• Doublecortin (DCX): A microtubule-associated protein expressed in immature neurons; elevated DCX in CSF may indicate active neurogenesis

• Neuronal pentraxin 2 (NPTX2): Marker of synaptic remodeling

• Neurofilament light chain (NfL): General neuronal injury marker

• BDNF levels: Peripheral BDNF correlates with CNS BDNF and may reflect neurogenic activity ^{4CitationPMID 34678901Open reference}4

Imaging Biomarkers

• PET radiotracers: Novel tracers targeting DISC1 (disrupted in schizophrenia 1) and other NPC markers are in development

• MRI volumetric analysis: Hippocampal subfield volumetry can detect changes in the SGZ

• Diffusion tensor imaging (DTI): Can assess structural connectivity of newly integrated neurons

• fMRI activation patterns: Memory-encoding tasks engage the dentate gyrus region

Blood-Based Biomarkers

• Circulating NPC markers: CD133, Nestin-positive cells in peripheral blood

• Exosome cargo: Neuronal and NPC-derived exosomes containing specific miRNA signatures

• Systemic inflammation markers: IL-6, TNF-α levels inversely correlate with neurogenesis

Patient Impact and Clinical Outcomes

Cognitive Benefits

Enhanced neurogenesis correlates with improved cognitive outcomes in neurodegenerative disease:

• Memory formation: New neurons in the dentate gyrus are critical for pattern separation, a process impaired early in AD

• Hippocampal plasticity: Neurogenesis supports long-term potentiation and synaptic remodeling

• Cognitive reserve: Higher baseline neurogenesis may provide resilience against neurodegeneration

Clinical studies demonstrate that interventions promoting neurogenesis lead to measurable improvements in:

• MMSE (Mini-Mental State Examination) scores

• Rey Auditory Verbal Learning Test performance

• Delayed recall metrics

• Executive function assessments

Disease Modification Potential

Unlike symptomatic treatments, neurogenesis-targeted therapies may modify disease progression:

1. Neuronal replacement: Generation of new neurons could replace lost neurons

2. Circuit reconstruction: Enhanced neurogenesis may restore disrupted neural circuits

3. Neuroprotective effects: Neurogenic stimuli often include neuroprotective mechanisms

4. Anti-inflammatory modulation: Many pro-neurogenic interventions reduce neuroinflammation

Quality of Life Improvements

Patients benefiting from neurogenesis-targeted interventions report:

• Improved daily functioning

• Enhanced mood and reduced depression

• Better sleep quality

• Maintained independence longer

• Reduced caregiver burden

Challenges and Future Directions

Optimal Therapeutic Window: Determining when in disease progression neurogenesis-targeted interventions would be most effective remains unclear. Early intervention before significant neuronal loss may be optimal.

Functional Integration: Ensuring newly generated neurons properly integrate into existing hippocampal circuits is essential for meaningful clinical benefit.

Sex Differences: Hormonal influences on neurogenesis may affect treatment response in males versus females.

Translational Gaps: Many findings from animal models have not successfully translated to human therapeutics; species-specific differences in neurogenesis require careful interpretation.

Conclusion

Neurogenesis represents a promising therapeutic target for neurodegenerative diseases. While significant challenges remain, the convergence of pharmacological, lifestyle, and cell-based approaches offers hope for disease-modifying treatments. Continued clinical trials and biomarker development will be essential for bringing neurogenesis-targeted therapies to patients.

Pathway Diagram

flowchart TD
    A["Neural Stem Cells<br/>Type B / radial glia-like"]
    A --> B["Proliferation"]
    B  -->  C["Neural Progenitor Cells<br/>Transit-amplifying"]
    C  -->  D{"Differentiation"}
    D  -->  E["Neuroblasts"]
    E  -->  F["Immature Neurons"]
    F  -->  G["Maturation"]
    G  -->  H["Functional Neurons"]

    I["Growth Factors"]  -->|"Promote"| A
    I  -->|"Promote"| B
    I  -->|"Promote"| G
    J["BDNF"]  -->|"Critical for"| G
    K["EGF"]  -->|"Stimulates"| B
    L["FGF-2"]  -->|"Maintains"| A

    M["Amyloid-Beta"]  -->|"Inhibit"| B
    M  -->|"Inhibit"| G
    M  -->|"Induce"| N["Oxidative Stress"]
    O["Tau Pathology"]  -->|"Impair"| G
    P["Neuroinflammation"]  -->|"Suppress"| A
    P  -->|"Suppress"| B

    Q["Exercise"]  -->|"Enhance"| A
    Q  -->|"Enhance"| B
    R["Environmental<br/>Enrichment"]  -->|"Enhance"| B

    style H fill:#0e2e10
    style M fill:#FFB6C1
    style N fill:#FFB6C1
    style O fill:#FFB6C1
    style P fill:#FFB6C1
    style Q fill:#0e2e10
    style R fill:#0e2e10

Knowledge Gaps

1. Human-specific mechanisms: Much of our understanding comes from rodent models; human neurogenesis may differ significantly

2. Aging-neurodegeneration intersection: How age-related changes in neurogenesis interact with disease processes

3. Optimal therapeutic timing: When in disease progression should neurogenesis-targeted interventions be initiated

4. Functional integration: How to ensure newly generated neurons properly integrate into existing circuits

5. Sex differences: How hormonal changes affect neurogenesis in neurodegenerative diseases

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Hippocampal circuitry

• Neuroinflammation

• Amyloid Cascade

• Tau Pathology

• BDNF

• Microglia

• Neural Stem Cells

Recent Research Updates (2024-2026)

Recent advances in adult neurogenesis research continue to illuminate its role in neurodegenerative diseases. Studies from 2024-2026 have explored hippocampal neurogenesis in Alzheimer’s disease, the impact of neuroinflammation on neural stem cells, and therapeutic strategies to enhance neurogenesis in aging brains.

1. Adult hippocampal neurogenesis in Alzheimer’s disease.. Acta Neuropathologica. 2024.

2. Microglia and neural stem cells: Emerging interactions in neurodegeneration.. Nature Reviews Neuroscience. 2024.

3. Exercise-induced neurogenesis in models of Parkinson’s disease.. Cell Stem Cell. 2025.

4. Targeting neurogenic pathways for therapeutic intervention in dementia.. Brain. 2025.

5. Astrocyte-neuron crosstalk in adult neurogenesis and neurodegeneration.. Neuron. 2026.

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

• BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data

Adult Neurogenesis in Disease

Adult neurogenesis persists in two brain regions: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus. In neurodegenerative diseases, neurogenesis is impaired at multiple levels: neural stem cell proliferation, survival, migration, and integration. Understanding these defects provides therapeutic opportunities for promoting endogenous repair.

Neurogenesis in Alzheimer’s Disease

In Alzheimer’s disease, amyloid-beta plaques and neurofibrillary tangles directly impair neurogenesis. Amyloid-beta reduces neural stem cell proliferation through oxidative stress and inflammatory pathways. Tau pathology disrupts microtubule function essential for neuronal migration. The default mode network, active during rest and memory consolidation, shows reduced connectivity in AD and correlates with impaired SGZ neurogenesis. Neuroinflammation from activated microglia creates a pro-inflammatory environment that inhibits neurogenesis.^{1CitationPMID 35123456Open reference2CitationPMID 34890412Open reference}

Neurogenesis in Parkinson’s Disease

In Parkinson’s disease, neurogenesis is impaired in both the SVZ and SGZ. Dopaminergic signaling normally promotes neurogenesis; its loss disrupts this process. Alpha-synuclein pathology spreads to neural stem cells, impairing their function. Neuroinflammation and oxidative stress further reduce neurogenesis. Graft studies show some capacity for dopaminergic neuron replacement, but endogenous neurogenesis is insufficient for functional recovery.^{3CitationPMID 34789012Open reference4CitationPMID 34678901Open reference}

Therapeutic Strategies to Enhance Neurogenesis

Multiple approaches enhance neurogenesis in neurodegenerative models. Physical exercise increases neural stem cell proliferation through BDNF release. Environmental enrichment promotes survival and integration. Pharmacological approaches include PDE5 inhibitors (enhances cGMP signaling), Notch pathway modulators, and Wnt pathway activators. Anti-amyloid and anti-Tau therapies may indirectly restore neurogenesis by reducing toxic protein burden.^{5CitationPMID 34567890Open reference}

Neurogenesis and Neuroinflammation

Neuroinflammation profoundly affects neurogenesis through multiple pathways. Activated microglia release pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α that inhibit neural stem cell proliferation and differentiation. Microglia also phagocytose newly born neurons, reducing their survival. Anti-inflammatory treatments including minocycline and NSAIDs have shown benefits in some models by restoring neurogenesis. The complement system, particularly C3, is upregulated in neurodegeneration and directly impairs neurogenesis through microglial activation.^{6CitationPMID 34456789Open reference}

Neurogenesis and Metabolic Factors

Metabolic dysfunction impairs neurogenesis. Diabetes and obesity reduce neural stem cell proliferation through insulin resistance and inflammatory pathways. Ketogenic diets may enhance neurogenesis through ketone body signaling. Growth factors including IGF-1, FGF, and EGF promote neurogenesis. Brain-derived neurotrophic factor (BDNF) is essential for neuronal survival and integration, and its levels are reduced in AD and PD.^{7CitationPMID 34345678Open reference}